Quantifying Damages In Product Launch Delay Allegations
In March, indirect purchasers of Novo Nordisk's GLP-1 drug Victoza filed a lawsuit alleging Novo Nordisk conspired to delay generic entry by approximately 16 months, from February 2023 to June 2024.[1]...To view the full article, register now.
Already a subscriber? Click here to view full article